Keating Investment Counselors’s GSK GSK Stock Holding History

Keating Investment Counselors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.74M	Sell	166,818 -8,350	-5%	-$442K	2.4%	8
2026 Q1	$9.67M	Sell	175,168 -4,941	-3%	-$268K	2.39%	10
2025 Q4	$8.83M	Buy	180,109 +578	+0.3%	+$27K	2.45%	7
2025 Q3	$7.75M	Sell	179,531 -7,270	-4%	-$284K	2.21%	8
2025 Q2	$7.17M	Sell	186,801 -2,005	-1%	-$76.6K	2.17%	8
2025 Q1	$7.31M	Buy	188,806 +25,201	+15%	+$923K	2.21%	7
2024 Q4	$5.53M	Buy	+163,605	New	+$5.89M	1.73%	15
2023 Q1	–	Sell	-197,918	Closed	-$6.95M	–	82
2022 Q4	$6.95M	Buy	197,918 +56,742	+40%	+$1.89M	2.72%	14
2022 Q3	$4.16M	Buy	141,176 +420	+0.3%	+$15.9K	1.86%	19
2022 Q2	$7.66M	Sell	140,756 -706	-0.5%	-$39K	3.23%	9
2022 Q1	$7.7M	Hold	141,462	–	–	3.3%	10
2021 Q4	$7.8M	Buy	141,462 +106	+0.1%	+$5.51K	3.45%	8
2021 Q3	$6.75M	Buy	141,356 +1,608	+1%	+$80.8K	3.16%	11
2021 Q2	$6.96M	Buy	+139,748	New	+$6.71M	3.19%	10

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Keating Investment Counselors's GSK Position: Q2 2026 in Review

Keating Investment Counselors reduced its GSK (GSK) stake by 4.8% in Q2 2026, selling an estimated $442K and leaving 166,818 shares worth $8.74M. The position accounts for 2.4% of the portfolio, ranked #8.

Keating Investment Counselors first reported a position in GSK in Q2 2021 and has held it in 14 quarters since. The position peaked at $9.67M in Q1 2026. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Keating Investment Counselors held 166,818 shares of GSK worth $8.74M as of Q2 2026.
Keating Investment Counselors sold 8,350 GSK shares in Q2 2026, an estimated $442K.
GSK made up 2.4% of Keating Investment Counselors's portfolio in Q2 2026, its #8 holding.
Keating Investment Counselors first reported a position in GSK in Q2 2021 and has held it in 14 quarters since.
Keating Investment Counselors's GSK position peaked at $9.67M in Q1 2026.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Keating Investment Counselors's 13F filing for Q2 2026, filed 16 Jul 2026.